Akari Therapeutics Plc Files ADR Registration

TL;DR

AKARI files ADR registration, opening door for US investors.

AI Summary

Akari Therapeutics Plc filed an F-6/A form on March 31, 2026, to register American Depository Receipt shares. The filing was accepted on the same date. Deutsche Bank Trust Co Americas is acting as the depositary bank for these ADRs.

Why It Matters

This filing indicates Akari Therapeutics is preparing to offer its shares in the form of American Depository Receipts, potentially broadening its investor base and access to capital.

Risk Assessment

Risk Level: low — This is a routine registration filing for ADRs and does not inherently represent new financial risk for the company.

Key Players & Entities

• Akari Therapeutics Plc (company) — Subject company
• Deutsche Bank Trust Co Americas (company) — Depositary Bank
• 2026-03-31 (date) — Filing Date

FAQ

Filing Documents

• d12123390_f-6a.htm (F-6/A) — 224KB
• 0000919574-26-001972.txt ( ) — 225KB

DESCRIPTION OF SECURITIES TO BE REGISTERED

DESCRIPTION OF SECURITIES TO BE REGISTERED CROSS REFERENCE SHEET Item Number and Caption Location in Form of American Depositary Receipt ("Receipt") Filed Herewith as Prospectus 1. Name of depositary and address of its principal executive office Face of Receipt, Introductory article and bottom center 2. Title of Receipts and identity of deposited securities Face of Receipt, Top center Terms of Deposit: (i) The amount of deposited securities represented by one American Depositary Share Face of Receipt, Upper right corner (ii) The procedure for voting, if any, the deposited securities Paragraph (15) (iii) The collection and distribution of dividends Paragraph (13) (iv) The transmission of notices, reports and proxy soliciting material Paragraphs (12), (14) and (15) (v) The sale or exercise of rights Paragraphs (2), (6), (13), (16) and (21) (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization Paragraphs (13) and (16) (vii) Amendment, extension or termination of the deposit arrangements Paragraphs (20) and (21) (no provision for extensions) (viii) Rights of holders of Receipts to inspect the transfer books of the depositary and the list of holders of Receipts Paragraph (12) (ix) Restrictions upon the right to deposit or withdraw the underlying securities Paragraphs (2), (3) and (4) (x) Limitation upon the liability of the depositary Paragraphs (6), (10), (15), (16), (17), (18) and (21) 3. Fees and charges which may be imposed directly or indirectly against holders of Receipts Paragraph (9) Item 2. AVAILABLE INFORMATION Paragraph (12) Akari Therapeutics, Plc is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, the Securities and Exchange Commission (the "Commission"). These reports may be retrieved from the Commission's website (www.sec.gov) and may be inspected and copi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, Deutsche Bank Trust Company Americas, on behalf of the legal entity created by the Deposit Agreement, by and among Akari Therapeutics, Plc, Deutsche Bank Trust Company Americas, as depositary, and all Owners and Beneficial Owners from time to time of American Depositary Shares evidenced by American Depositary Receipts issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 4 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 31, 2026. Legal entity created by the Deposit Agreement for the issuance of American Depositary Receipts evidencing American Depositary Shares representing ordinary shares of Akari Therapeutics, Plc Deutsche Bank Trust Company Americas, solely in its capacity as Depositary By: /s/ Michael Curran Name: Michael Curran Title: Vice President By: /s/ Robert Martello Name: Robert Martello Title: Director

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, Akari Therapeutics, Plc certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 4 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on March 31, 2026. Akari Therapeutics, Plc By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: President and Chief Executive Officer Each person whose signature appears below hereby constitutes and appoints Abizer Gaslightwala and Kameel Farag, and each of them severally, his true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his name, place and stead in any and all capacities the Registration Statement and any and all amendments thereto (including post-effective amendments) and any documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto each of said attorneys full power to act with or without the other, and full power and authority to do and perform, in his name and on his behalf, every act whatsoever which such attorneys, or any one of them, may deem necessary or desirable to be done in connection therewith as fully and to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 4 to Registration Statement on Form F-6 has been signed by the following persons in the capacities indicated on March 31, 2026.

Signatures

Signatures Capacity /s/ Abizer Gaslightwala Abizer Gaslightwala President, Chief Executive Officer, and Director (principal executive officer) /s/ Kameel D. Farag Kameel D. Farag Interim Chief Financial Officer (principal financial officer and accounting officer) /s/ Hoyoung Huh Hoyoung Huh, M.D., Ph.D. Chairman /s/ Samir R. Patel Samir R. Patel, M.D. Director /s/ Ray Prudo Ray Prudo, M.D. Director /s/ James Neal James Neal Director /s/ Sandip I. Patel. Sandip I. Patel. Director /s/ Robert Bazemore Robert Bazemore Director SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT Under the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Akari Therapeutics, Plc has signed this Post-Effective Amendment No. 4 to Registration Statement on Form F-6 in the City of Cambridge, Commonwealth of Massachusetts, on March 31, 2026. Celsus Therapeutics, Inc. By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: Authorized Representative INDEX TO EXHIBITS Exhibit Number (a)(5) Form of Amendment No. 4 to Deposit Agreement (e) Rule 466 Certification Exhibit (a)(5) AMENDMENT NO. 4 TO DEPOSIT AGREEMENT AMENDMENT No. 4 (the "Amendment") dated as of March 18, 2026 to the Deposit Agreement (the "Effective Date"), dated as of December 7, 2012, as previously amended as of December 24, 2013, September 9, 2015 and August 17, 2023 (as amended from time to time, the "Deposit Agreement"), by and among (i) Akari Therapeutics, Plc, a company incorporated under the laws of England and Wales (and together with any of its successors, collectively referred to as the "Company"), (ii) Deutsche Bank Trust Company Americas, an indirect wholly owned subsidiary of Deutsche Bank A.G., acting in its capacity as depositary, and any successor depositary hereunder (the "Depositary"), and (iii) all Holders and Beneficial Owners of American Depositary Shares evidenced by American Depositary Receipts issued thereund

View Full Filing

View this F-6/A filing on SEC EDGAR